Idexx Laboratories Inc. (IDXX) Shares Bought by Headinvest LLC
Headinvest LLC boosted its position in Idexx Laboratories Inc. (NASDAQ:IDXX) by 8.0% during the second quarter, Holdings Channel reports. The institutional investor owned 67,751 shares of the company’s stock after buying an additional 5,000 shares during the period. Idexx Laboratories accounts for 2.4% of Headinvest LLC’s portfolio, making the stock its 8th largest position. Headinvest LLC owned 0.08% of Idexx Laboratories worth $6,291,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently added to or reduced their stakes in IDXX. Nordea Investment Management AB purchased a new stake in Idexx Laboratories during the second quarter worth about $176,000. Canada Pension Plan Investment Board purchased a new stake in Idexx Laboratories during the first quarter worth about $196,000. Strs Ohio purchased a new stake in Idexx Laboratories during the second quarter worth about $196,000. Daiwa Securities Group Inc. purchased a new stake in Idexx Laboratories during the second quarter worth about $204,000. Finally, FirstMerit Bank N A Trustee purchased a new stake in Idexx Laboratories during the second quarter worth about $236,000. 91.58% of the stock is owned by institutional investors and hedge funds.
Idexx Laboratories Inc. (NASDAQ:IDXX) traded up 0.91% during trading on Thursday, reaching $113.09. The company had a trading volume of 442,241 shares. The firm’s 50-day moving average price is $111.08 and its 200 day moving average price is $92.50. Idexx Laboratories Inc. has a one year low of $63.48 and a one year high of $115.06. The firm has a market capitalization of $10.13 billion, a P/E ratio of 51.26 and a beta of 0.56.
Idexx Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 2nd. The company reported $0.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.12. The business had revenue of $467 million for the quarter, compared to analysts’ expectations of $444.83 million. Idexx Laboratories had a negative return on equity of 414.67% and a net margin of 11.94%. The firm’s quarterly revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.60 EPS. Equities analysts forecast that Idexx Laboratories Inc. will post $2.36 earnings per share for the current fiscal year.
A number of analysts have issued reports on IDXX shares. Canaccord Genuity reissued a “buy” rating and issued a $120.00 target price on shares of Idexx Laboratories in a research report on Monday, August 22nd. Stifel Nicolaus lifted their price target on Idexx Laboratories from $120.00 to $125.00 and gave the company a “buy” rating in a research report on Tuesday, August 16th. Zacks Investment Research upgraded Idexx Laboratories from a “hold” rating to a “buy” rating and set a $121.00 price target for the company in a research report on Thursday, August 4th. Finally, Northcoast Research upgraded Idexx Laboratories from a “sell” rating to a “neutral” rating in a research report on Wednesday, August 3rd. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Idexx Laboratories presently has an average rating of “Buy” and a consensus price target of $105.20.
In other news, Director Rebecca M. Henderson sold 9,924 shares of the stock in a transaction on Thursday, August 25th. The stock was sold at an average price of $110.43, for a total transaction of $1,095,907.32. Following the transaction, the director now directly owns 16,678 shares of the company’s stock, valued at approximately $1,841,751.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director William T. End sold 5,000 shares of the stock in a transaction on Friday, August 5th. The shares were sold at an average price of $108.50, for a total value of $542,500.00. Following the transaction, the director now directly owns 53,564 shares in the company, valued at $5,811,694. The disclosure for this sale can be found here. Insiders own 2.79% of the company’s stock.
About Idexx Laboratories
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Idexx Laboratories Inc. (NASDAQ:IDXX).
Receive News & Ratings for Idexx Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.